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Before going into a discussion of the diagnosis 
and treatment of carcinoma of the thyroid, I would 
like to make a few observations on the means of 
detection. 
Thyroid scanning, in my opinion, is useful only 
in the study of nodules. We see many patients who 
have had scans for diffuse thyroid enlargement, and I 
feel that in this instance, scans are useless. The basic 
reason for the scan is to discover which pieces of 
thyroid tissue have to be removed because of possible 
malignancy. I would like to emphasize, that the 
physician has to do the scan himself. He has to 
localize the nodule, properly mark it on the scan, and 
remain during the scan, as the patient may move his 
neck, thus moving the position of the nodule in 
reference to the marks. We have seen scans in the 
early days of isotope scanning where the technician, 
who was not taught to palpate the thyroid, marked 
the scan. This system is inadequate, as errors can oc-
cur. 
Using the T-3 suppression test, the criteria for 
suppression is a fall in uptake below 20% in 24 hours 
after a week on T-3, 150µ daily. However, the normal 
uptake is often below 20%, and hyperthyroid patients 
may also have less than 20% uptake, so the test is los-
ing some of its specificity. I think the criteria for the 
suppression test should be changed, or the interpreta-
tion of it, to indicate that there is "no significant" fall 
in uptake after T-3 for a week. It is very difficult to es-
tablish such criteria, because I do not know what nor-
mal figures to give. We recently saw a patient with a 
• The following is an edited transcription of a lecture presented by 
Dr. Kirkland at the Postgraduate Course in Nuclear Medicine, 
February 27, 1975, in Williamsburg, Virginia. 
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nodule who had 8% uptake in 24 hours prior to T-3. 
We went ahead with T-3 suppression, and he had 7% 
after T-3. We did not know what to do or how to in-
terpret this. We treated the patient with radioactive 
iodine, thinking that the nodule was not suppressible, 
and the other lobe did reappear on later scanning. 
This patient had an autonomous nodule with an 8.0% 
uptake. 
In my opinion, 3- and 5-hour uptakes are ab-
solutely essential. I would not want an uptake run 
only at 24-hour intervals, because we do see patients 
who have taken iodides or, unknown to us, an-
tithyroid drugs and who have normal 24-hour up-
takes but who have blocked thyroid function and are 
not making thyroid hormone at the moment. 
Therefore, it is necessary to run 3- and 5-hour up-
takes to identify this blocked type of function and, if 
diagnosis is not clear at that time, at a later 24-hour 
· point. 
In the hot nodule with low radioiodine uptake 
where the T-3 suppression test may not be of great 
value, one can give TSH and do a scan afterward to 
see if the other lobe reappears. If it does reappear, in-
dications are that the nodule is an autonomous one 
which was suppressing TSH. 
I now want to discuss the diagnosis and treat-
ment of carcinoma of the thyroid. Carcinoma of the 
thyroid gland is both rare and common. It is a fre-
quent diagnosis on pathological sections, but clini-
cally it is a rare disease. Very few patients die from 
carcinoma of the thyroid. Each of us has seen so few 
thyroid carcinomas of clinical significance that it is 
difficult to gather a series sufficiently large to deter-
mine what treatment techniques are best. As some 
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evidence of the incidence, Dr. Fratkin showed that in 
one hundred cases of thyroid nodules 70% were cold. 
Of the 70% that were cold, he said 15% were car-
cinomatolis. That is a high incidence of carcinoma of 
the thyroid. Recently, a student and I went around on 
the wards at the Medical College of Virginia and felt 
every patient's thyroid reg; rdless of what the patient 
had been admitted for . Thirty-three percent of the 
women incidentally had palpable nodular thyroid 
disease. If we take these female patients with 
nodules-70% of them cold and 15% of them with 
carcinoma-3.48% of women in the Medical College 
of Virginia should have carcinoma of the thyroid. 
Obviously these figures are not true clinically. Even 
the pathologist has problems in diagnosing thyroid 
malignancy. Thyroid-stimulating hormone stimula-
tion of the thyroid makes it so hypertrophic that 
sometimes the thyroid looks malignant although it 
doesn't behave that way. 
In patients with carcinoma of the thyroid, the 
natural course of the disease is variable, so that a 
long-term follow-up is necessary to determine what 
happens to them. One cell type, such as papillary car-
cinoma of the thyroid, might change to follicular, or 
the metastases may show at the same time different 
pathological types. Any treatment I propose, 
therefore, would have to be very arbitrary. 
I would like to mention something about the 
etiology of the carcinoma of the thyroid. Two 
Australians, Purves and Geishbach, in 1948, gave rats 
thiourea for two of their three-year life spans and 
found that 100% of the rats developed carcinoma of 
the thyroid. (This fact does not stop us from giving 
propylthiouracil to patients, and some clinics ad-
vocate this as the best treatment for 
hyperthyroidism). They stated in their article, "We 
think that the administration of thyroid extract to 
these rats would have prevented this." They gave 
thiourea to rats after. hypophysectomies and none of 
these animals developed carcinoma of the thyroid. 
This suggests to me that the etiology for the car-
cinoma, or an etiological factor, was the TSH level 
which rose in the thiourea-treated rats and stimulated 
a blocked gland. That was the first finding that led me 
to think that carcinoma might be produced by long-
term TSH stimulation of a blocked or damaged 
thyroid gland. There is also an increased incidence of 
carcinoma of the thyroid in patients who have con-
genital enzyme blocks. One type of congenital en-
zyme block is followed by nearly 100% incidence of 
carcinoma of the thyroid-another fact that makes 
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me think that TSH stimulation might lead to car-
cinoma. There is a higher incidence of carcinoma of 
the thyroid in thyroiditis where the gland may be in-
jured. The TSH may rise and the same circumstances 
occur. Irradiation of the neck in childhood is another 
etiologic factor. There are also cases of thyroid car-
cinoma which are TSH dependent. These tumors 
tend to grow more rapidly if the TSH levels are high. 
We should, therefore, keep the TSH low in patients 
who have carcinoma of the thyroid. This concept has 
been an important influence in my treatment of 
thyroid patients. Once hyperthyroidism is eliminated, 
I think anyone with thyroid disease should be on 
long-term suppressive thyroid hormones. 
These factors led me to review the histories of 
patients with carcinoma of the thyroid at the Medical 
College of Virginia in order to see if I could find a 
thyroid-damaging factor. Fifty percent of the patients 
had had some thyroid destructive disease, such as 
thyroiditis or colloid goiter, or treatment for thyroid 
suppression, such as surgery. None of them had had 
radioiodine therapy, but I think the incidence of car-
cinoma of the thyroid might increase after radio-
iodine if we live long enough to observe this course. 
How do we diagnose the carcinoma of the 
thyroid? Most cases are not diagnosed by symptoms, 
although there are some symptoms, such as 
hoarseness or a tracheal narrowing shown on AP and 
lateral x-rays. Hoarseness suggests that the recurrent 
laryngeal nerves might be invaded, and this might in-
dicate the possibility of carcinoma, especially if it is 
accompanied by a mass in the thyroid area. 
Dysphagia is suspicious. X-ray studies of the es-
ophagus showing real obstruction are helpful and do 
suggest that there is true disease present and not just 
an anxiety globus hystericus. We recently noted a 
bruit over the thyroid gland in the absence of 
hyperthyroidism. This indicated that there was high 
vascularity and suggested the possibility of 
Thyroid 
Pathology found in "hot" nodules 
Nodular colloid goiter 
Hyperplastic goiter 
Adenoma 
Carcinoma 
Unclassified 
Fig. I-Pathology in "hot" nodules at MCV. 
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Pathology found in cold nodules ( 184) 
Nodular colloid goiter 
Chronic thyroiditis 
Adenoma 
Carcinoma 
Unclassified 
58% 
4% 
17% 
13% 
8% 
Fig. 2-Pathology is 184 cold nodules at MCV. 
malignancy. A distant metastasis might be a hint of 
carcinoma of the thyroid. If there are nodules, we 
want to do scans. If the scan shows a cold nodule, 
carcinoma is a prime possibility. Figure I shows the 
pathology we have seen in our "hot" nodules. 
Nodular colloid goiter was found in 70% of cases, 
hyperplastic goiter (we are not sure what the 
pathologist meant by this as these were supposedly 
nontoxic patients) in 15%, adenoma in 15%, but no 
carcinoma. Figure 2 shows the pathology in 184 cold 
nodules which were removed. Thirteen percent were 
carcinomas of the thyroid. 
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Fig. 3-AP scan of patient with suspect nodule. 
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Fig. 4-0blique scan of same patient, revealing cold nodule. 
I want to emphasize the importance of lateral 
scans. Figure 3 is an AP scan of a patient who had 
had a nodule. One might think that this was a func-
tional nodule and not malignant. But on the lateral or 
oblique scan (Fig. 4), a cold nodule is seen in front of 
the radioactivity. Figure 5 shows a nodule that might 
be interpreted as a hot nodule. There is suspicion that 
it might not be a hot nodule, however, for the center 
of the gland is thicker, and one would think it would 
have a higher radioactivity. On the lateral scan, it is 
confirmed as a cold nodule. 
The treatment of carcinoma of the thyroid varies 
with the cell type, and Figure 6 snows the main types 
of the disease. The first approach to treatment of car-
cinoma of the thyroid is surgery. The extent of the 
surgery depends on the type of lesion. A biopsy with 
a frozen section will indicate what type of malignancy 
one is dealing with. The nodule should be removed 
along with any suspect tissue, and if it is carcinoma 
on a frozen section, a total thyroidectomy is in-
dicated. The only exception would be that I would 
ask the surgeon not to take the parathyroid glands. 
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Fig. 5-Left. AP scan of possible cold nodule; Right. Confirmed on lateral scan. 
As this might be difficult, he would perform a nearly 
total thyroidectomy. Myxedema as a result of surgery 
is of no concern because the patient will be placed on 
thyroid extract. All patients with carcinoma of the 
thyroid should be on thyroid extract for the rest of 
their lives in the hope that hormonal suppression of 
the tumor will be achieved, just as one might treat 
carcinoma of the breast with appropriate hormonal 
treatment. Radical neck dissection is not often my 
choice. The surgeon usually decides this. If he feels 
that the nodes are within the range of surgical resec-
tion, he should try to get them out, but in my opin-
ion, severely disfiguring, radical neck dissection is of 
no great value. The prognosis for carcinoma of the 
thyroid is so good that, other than for anaplastic 
types, I would not urge extensive neck dissection. In a 
medullary carcinoma, there is one follow-up technique 
and that is to check on calcitonin levels, because 
this offers a marker for continuing disease. If the 
calcitonin levels were high before removal and 
afterwards fell to normal, it would be very reassuring 
that the malignancy had been completely removed. If 
calcitonin levels rose in the future, they would in-
dicate that the carcinoma had recurred and that 
further treatment should be considered. 
There is a difference of opinion regarding the 
surgical follow-up schedule. Some authors would 
wait a month and do a radioactive iodine uptake 
Classification of Thyroid Neoplasms 
A. Adenoma 
B. Carcinoma 
I. Adenoma malignum 
2. Papillary 
3. Follicular 
4. Medullary 
5. Anaplastic 
Fig. 6-Main types of thyroid disease. 
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study to see if there is any residual thyroid tissue in 
the neck. They would ablate it with radioactive iodine 
and put the patient on thyroid hormone while waiting 
to see whether the patient develops further disease. 
This seems to me unnecessary as the patient may have 
already been cured. I would put the patient on 
thyroid hormone after the initial thyroidectomy and 
wait. If disease appears, I would stop the thyroid 
replacement and do a 1311 scan. If there is uptake of 
131 I in the residual thyroid area, a thyroid ablative 
dose of 1311 should be given. In one to two months, a 
tracer dose should be given to see whether there is 
any retention of the isotope after 48 hours. At the 
Medical College of Virginia, we determine 24- and 
48-hour urinary excretions of 1311 at that stage, and if 
there is any significant retention (if the patient ex-
cretes less than 90% of the radioiodine in the urine in 
48 hours), we scan the whole body searching for areas 
of retention and treat with large doses of radioiodine. 
If there were significant retention, we would try to 
stimulate maximal uptake of radioactive iodine prior 
to treatment by giving TSH intravenously or intra-
muscularly for three days and repeat the 1311 uptake. 
Should there be increasing retention, I would keep up 
the TSH for three more days until the maximal uptake 
was reached, because this may be the only opportunity 
to get an excellent uptake in the tumor. Therefore, I 
would continue TSH until I obtained maximum 
retention of the tracer dose, then give a large dose of 
radioactive iodine (150 millicuries of radioiodine), 
hoping to obtain the maximum uptake in the tumor. 
After radioiodine had had a chance to accumulate 
in the gland, I would put the patient on triiodo-
thyronine ( one of the few clinical uses for this 
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hormone in treatment) in order to suppress TSH in 
the interim, while waiting for the effect of the dose. 
The patient should be kept on that dose for about six 
weeks. The dose should then be discontinued and the 
patient retested with radioactive iodine in eight 
weeks. As long as there is uptake of radioactive 
iodine or retention of the isotope with less than 90% 
excretion in 24 hours, I would continue to treat the 
patient with radioactive iodine at approximately two-
month intervals until I had no further retention of the 
radioactive material. Of course, this has to be 
monitored by blood counts, primarily platelet counts. 
We have not seen significant platelet reduction until 
we have given 300 to 400 millicuries of radioiodine. 
Once I had achieved as much radioactive iodine treat-
ment as possible, that is, there was no longer any 
retention of the isotope 48 hours after a tracer dose, I 
would put the patient on totally suppressive and 
replacement doses of levothyroxine or triiodo-
thyronine. The triiodothyronine is used because it 
can be stopped more quickly, and its effect disappears 
more quickly. An additional method of treatment 
to consider, when radioactive treatment was no 
longer effective, would be x-ray therapy to any areas 
that were causing symptoms. 
The major point I would like to make is that we 
should try to prevent thyroid carcinoma by ad-
ministration of thyroid hormones to all patients with 
potentially high TSH and damaged-thyroid disease, 
using suppressive doses of levothyroxine. In my opin-
ion, all patients who have thyroid disease should be 
treated with thyroid hormone indefinitely, once 
hyperthyroidism has been eliminated. 
